OncoPrecision announces $3.3 million in Seed Funding to further develop its Patient Micro Avatar technology which seeks to recreate cancer patients' disease ex-vivo.

The funding was closed in April with the participation of SOSV's IndieBio, GRIDX, New York Ventures (the venture capital arm of the State of New York), Creative Ventures, Fundacion Para el Progreso de la Medicina (a high-complexity diagnostics lab where the company's Argentine lab is based), exited biotech and non-biotech founders, as well as strategic angel investors and family offices. OncoPrecision has raised a total of $4.2 million to date.